Week In Review: Approved. 4 Dec 2020

US equity indexes were up on the week: DJIA +1.0%.  S&P 500 +1.7%, NASDAQ +2.1%.    On Wednesday, the UK became the first Western country to approve a Covid-19 vaccine when its regulator cleared the Pfizer/BioNTech vaccine.  Pfizer put out a press release titled: “Pfizer and BioNTech Achieve First Authorization in the World for a…

continue

Week In Review: Competing Forces – 20 November 2020

This week brought more positive news on the vaccine front. On Monday, Moderna announced that its Phase 3 study of mRNA-1273, its vaccine candidate against COVID-19, “has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%.” On Friday, Pfizer and BioNTech applied…

continue

Week In Review 13 November 2020

On Monday, Pfizer and BioNtech announced that their “vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis.” In this interview, Axios speaks with Pfizer CEO Albert Bourla about vaccine data, distribution, politics, and how he…

continue

Exante Data © 2024. All rights reserved. Personal Data Usage Policy


This site is provided for informational purposes only.  The information included in this site should not be used as the sole basis for making a decision as to whether or not to invest in any particular security. In making an investment decision, you must rely on your own examination of the securities and the terms of the offering. You should not construe the contents of these materials as legal, tax, investment or other advice, or a recommendation to purchase or sell any particular security.

The information included in this site is based upon information reasonably available to Exante as of the date noted herein. Furthermore, the information included in this site has been obtained from sources that Exante believes to be reliable; however, these sources cannot be guaranteed as to their accuracy or completeness. Information contained in this site does not purport to be complete, nor does Exante undertake any duty to update the information set forth herein. No representation, warranty or undertaking, express or implied, is given as to the accuracy or completeness of the information contained herein, by Exante, its members, partners or employees, and no liability is accepted by such persons for the accuracy or completeness of any such information.

This site contains certain “forward-looking statements,” which may be identified by the use of such words as “believe,” “expect,” “anticipate,” “should,” “planned,” “estimated,” “potential,” “outlook,” “forecast,” “plan” and other similar terms. Examples of forward-looking statements include, but are not limited to, estimates with respect to financial condition, results of operations, and success or lack of success of certain investment strategy. All are subject to various factors, including, but not limited to, general and local economic conditions, changing levels of competition within certain industries and markets, changes in interest rates, changes in legislation or regulation, and other economic, competitive, governmental, regulatory and technological factors affecting the operations of the companies identified herein, any or all of which could cause actual results to differ materially from projected results.